Dachaigh › Lymphoma Burkitt › Oklahoma › Oklahoma City
Sgrùdaidhean clionaigeach Lymphoma Burkitt ann an Oklahoma City, OK
Tha 7 sgrùdaidhean airson Lymphoma Burkitt a’ lorg phàirtichean aig làraichean ann agus timcheall air Oklahoma City (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
A’ fastadhÌre 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
A’ fastadhÌre 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
A’ fastadhÌre 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
A’ fastadhÌre 2
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
A’ fastadhÌre 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
A’ fastadhÌre 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
A’ fastadhÌre 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
Sgrùdaidhean Lymphoma Burkitt ann am bailtean eile
- Houston, TX21 sgrùdaidhean
- Philadelphia, PA16 sgrùdaidhean
- Milwaukee, WI16 sgrùdaidhean
- Chicago, IL15 sgrùdaidhean
- Cincinnati, OH13 sgrùdaidhean
- New York City, NY13 sgrùdaidhean
- Atlanta, GA12 sgrùdaidhean
- Aurora, CO11 sgrùdadh
- Seattle, WA11 sgrùdadh
- Durham, NC10 sgrùdaidhean
- Boston, MA10 sgrùdaidhean
- Kansas City, MO10 sgrùdaidhean
Sgrùdaidhean eile ann an Oklahoma City
- Aillse Sgamhain Neo-chealla-beag28 sgrùdaidhean
- Cancer Ovarian28 sgrùdaidhean
- Ailse Endometrial25 sgrùdaidhean
- Aillse colorectal22 sgrùdaidhean
- Aillse Prostata21 sgrùdaidhean
- Ailseachadh nan Sgamhan19 sgrùdaidhean
- Aillse a' bhroilleach17 sgrùdaidhean
- Ailse metastatach16 sgrùdaidhean
- Aillse (gach seòrsa)14 sgrùdaidhean
- Leukemia myeloid geur14 sgrùdaidhean
- Carcinoma Cealla Sgamach a' Chinn agus a' Mhuineil13 sgrùdaidhean
- Aillse sa bhlaire11 sgrùdadh
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.